Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,867 signal articles · 185 in last 24h · 157,418 total before filter · latest 1h ago
185last 24h
866last 7d
140● bullish (7d)
81● bearish (7d)
214publishers
AllMacro199Earnings138M&A102Regulatory18Product20Analyst23
Sentiment:bullishneutralbearishshow all (incl. clickbait)
How El Niño Will Supercharge Global Inflation
Barrons.com53d agoneutral
How El Niño Will Supercharge Global Inflation

It’s been 23 weeks since the U.S. began strikes on Iran, and we’re still in the midst of what feels like the hundredth attempt at peace talks. President Donald Trump said this week that a deal to reopen the Strait of Hormuz was close, but warned that strikes could resume if talks fall apart. This week I’m diving into El Niño, and how the sheer strength of this year’s weather event means that its effects will extend well beyond agriculture profit margins—it will hurt global central banks’ efforts to curb inflation.

Health Care Roundup: Market Talk
The Wall Street Journal53d agoneutral
Health Care Roundup: Market Talk

1655 GMT – Eli Lilly CEO David Ricks says on CNBC that Foundayo—the company’s recently launched once-daily GLP-1 pill—is expanding the market, not cannibalizing it even though it’s offered at lower prices. At the same time, access to weight-loss treatments continues to expand, further increasing the total addressable market, Ricks says. Eli Lilly is up 3%.

‘Perps’ Are the Risky New Derivatives That Could Amplify Stock Blowups
The Wall Street Journal53d agoneutral
‘Perps’ Are the Risky New Derivatives That Could Amplify Stock Blowups

Not really, but CME Group the granddaddy of derivatives exchanges, would like to keep it respectable. CME provides many products needed for the normal functioning of financial markets. Its business has also gotten a big lift from the explosion in retail options trading and the public’s embrace of leveraged and options income funds.

Sandisk shares slide as cautious guidance overshadows strong AI-driven growth
InvestorsHub53d agoneutral
Sandisk shares slide as cautious guidance overshadows strong AI-driven growth

Sandisk (NASDAQ:SNDK) shares fell in premarket trading on Thursday after the flash memory manufacturer issued first-quarter guidance that failed to meet investors’ elevated expectations, despite another quarter of exceptional growth fuelled by artificial intelligence demand. The company forecast fiscal first-quarter 2027 revenue of between $10.

AppLovin shares tumble as revenue miss and cautious outlook outweigh earnings beat
InvestorsHub53d agobearish
AppLovin shares tumble as revenue miss and cautious outlook outweigh earnings beat

AppLovin Corporation (NASDAQ:APP) shares plunged more than 14% in premarket trading on Thursday after the software company delivered quarterly earnings that exceeded expectations but failed to satisfy investors on revenue growth and forward guidance. For the second quarter ended 30 June, AppLovin reported adjusted earnings per share of $3.

Bloomberg53d agoneutral
Accell Enters Insolvency Process as KKR Pandemic Bike Bet Flops

(Bloomberg) -- Accell Group Holding BV, the bike maker whose €1.6 billion ($1.9 billion) buyout by KKR & Co. epitomized pandemic lockdown bets, has sought court protection in the Netherlands after running out of cash to pay its debts.Most Read from BloombergIran Says Agreement on Hormuz Shipping Reached With OmanGoogle AI Veterans Depart During Seismic Leadership ShiftMajor Hedge Funds Targeted in Wave of Attempted CyberattacksMicrosoft’s AI Sales Mostly Come From OpenAI, Disclosures ShowSpaceX’

Pressured by Tesla, European regulators keep 'Full Self-Driving' safety data secret
Reuters53d agoneutral
Pressured by Tesla, European regulators keep 'Full Self-Driving' safety data secret

Aug 6 () - Four months ago, the Netherlands approved Tesla’s Full Self-Driving (FSD) system and has since then advocated for its adoption across the EU. But Dutch road regulator RDW won’t tell the public why it concluded the driver-assistance system is safe or how it evaluated the technology, which for years has faced regulatory investigations and lawsuits over FSD-involved crashes in the United States.

PZ Cussons H2 Earnings Call Highlights
MarketBeat53d agoneutral
PZ Cussons H2 Earnings Call Highlights

PZ Cussons (LON:PZC) reported higher revenue, operating profit and free cash flow for the year ended May 31, 2026, as growth across its four lead markets and top 10 brands supported increased marketing investment and a materially lower debt position. Group revenue rose 5.4% to £541 million, represe

SpaceX lockup expires today, with stock bucking higher
Yahoo Finance53d agoneutral
SpaceX lockup expires today, with stock bucking higher

SpaceX insiders and early investors will be able to sell their stock for the first time on Thursday, when 911.5 million shares become eligible to trade — around 43% more than the 638.9 million shares the company floated in its June initial public offering.

How Novo Nordisk’s CEO Says He Is Shifting the Company’s Perspective
The Wall Street Journal53d agoneutral
How Novo Nordisk’s CEO Says He Is Shifting the Company’s Perspective

Doustdar was fairly fresh off an earnings call, but we connected to discuss a different milestone—his one-year anniversary in the CEO role, which is tomorrow. Introducing culture change had been part of the CEO’s mission since he landed the job, and he arrived with notes, having already worked at Novo Nordisk for 33 years.

Nutrien misses profit estimates as lower volumes blunt higher fertilizer prices
Reuters53d agobearish
Nutrien misses profit estimates as lower volumes blunt higher fertilizer prices

Aug 5 () - Nutrien missed analysts' estimates for second-quarter profit on Wednesday as lower potash and nitrogen sales volumes offset the ‌benefit of higher fertilizer prices at the world's largest potash ‌producer. Fertilizer producers have benefited from firmer nutrient prices this year, but earnings remain sensitive to ​shipment volumes, which reflect farmer demand and application activity.

Deal or No Deal, AstraZeneca Stock Is a Bargain
The Wall Street Journal53d agoneutral
Deal or No Deal, AstraZeneca Stock Is a Bargain

Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca’s chief executive, Pascal Soriot. After plunging on a Financial Times report of merger discussions with Bristol-Myers Squibb shares of AstraZeneca recovered somewhat when Reuters reported there are no ongoing talks. After rebuffing Pfizer’s $120 billion takeover bid in 2014, he steadily transformed AstraZeneca into one of the drug industry’s top growth stories.

European Indexes Rise as Earnings Drive Markets
Barrons.com53d agoneutral
European Indexes Rise as Earnings Drive Markets

European stock indexes rose in early trade as earnings stories drove increases. The Europe-wide Stoxx 600 added 0.3%, led by consumer-facing stocks and healthcare. London's FTSE 100 moved 0.3% higher, led by a 10.

Siemens shares plunge on disappointing guidance raise
AFP53d agobearish
Siemens shares plunge on disappointing guidance raise

German industrial giant Siemens on Thursday raised its profit outlook for the second time this year after a quarter boosted by AI spending, but its shares plunged after the forecast fell short of investors' hopes.But Siemens shares dropped six percent in early Frankfurt trading, with analysts pointing to expectations of higher full-year profits, as well as fears that new AI tools will disrupt Siemens's own software business.